Promising Developments in Alzheimer s Treatment: Tiziana Life Sciences Intranasal Foralumab Shows Significant Reduction in Microglia ActivationTiziana Life Sciences, a biotechnology company known for its innovative therapeutic approaches, has announced promising developments in the treatment of Alzheimer s disease. The company recently revealed that a moderate Alzheimer s patient treated with its intranasal Foralumab exhibited a significant reduction in microglia activation during a PET scan. This reduction is a crucial marker indicating the potential efficacy of Foralumab in mitigating neuroinflammation associated with Alzheimer s pathology.Microglia are the brain s primary immune cells and play a central...
In a strategic move that underscores its commitment to innovation in the biopharmaceutical sector, Tiziana Life Sciences has announced a collaborative agreement with Renaissance Lakewood, LLC, a notable player in Contract Development and Manufacturing Organizations (CDMO) specializing in nasal drug delivery. This partnership, revealed on February 21, 2025, centers around the advancement of Tiziana’s lead candidate, intranasal foralumab an anti-CD3 monoclonal antibody designed for the treatment of various neurodegenerative and inflammatory conditions. Optimizing the Future of Immunotherapy At the core of this collaboration lies the optimization of the formulation for intranasal foralumab, positioning Tizian...
On September 19, 2024, Tiziana Life Sciences, a biotechnology firm specializing in immunomodulation therapies, announced the receipt of a significant $4 million grant from the National Institutes of Health (NIH) to study a promising therapeutic approach for Alzheimer s disease (AD). This grant, awarded by the NIH s National Institute on Aging, will be led by Dr. Howard Weiner at Brigham and Women s Hospital, which has been designated as the key research site for this initiative.The focus of this grant is on the company’s lead candidate, intranasal foralumab, a fully human anti-CD3 monoclonal antibody. Intranasal administration offers a non-invasive route that may facilitate easier patient compliance and p...
In recent news, Tiziana Life Sciences has achieved a significant milestone in its pursuit of developing innovative immunomodulation therapies for various diseases, particularly non-active, secondary-progressive multiple sclerosis (na-SPMS). The biotechnology company has successfully obtained Fast Track Designation approval from the U.S. Food and Drug Administration (FDA) for its intranasal foralumab treatment. Furthermore, Tiziana has also submitted a request to obtain Orphan Drug Designation for the same therapy, aiming to provide a groundbreaking solution for na-SPMS patients.The Fast Track Designation approval signifies the FDA s recognition of the urgent need for effective treatment options for individua...
Multiple Sclerosis (MS) manifests as a neuroinflammatory and neurodegenerative disorder with significant patient morbidity. Secondary Progressive Multiple Sclerosis (SPMS) represents a stage of the disease characterized by progressive neurological decline independent of relapses. Traditional therapies provide limited efficacy in non-active Secondary Progressive Multiple Sclerosis (na-SPMS), prompting the need for innovative therapeutic approaches.Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) is a biotechnology company at the forefront of developing groundbreaking immunomodulation therapies. They have recently focused on novel drug delivery methods, including intranasal administration, to optimize therapeutic be...
Multiple sclerosis (MS) is a chronic autoimmune disease that affects the central nervous system, leading to significant disability and impairment in millions of individuals worldwide. The need for more effective and well-tolerated treatment options has prompted researchers to explore novel therapeutic approaches. In this article, we evaluate the groundbreaking findings announced by Tiziana Life Sciences Ltd. regarding their intranasal Foralumab therapy in two new MS patients. The positive outcomes observed in this study demonstrate the potential of Foralumab as a promising neuro-immunomodulation therapy, offering hope to individuals living with MS.Methods and Results:Tiziana Life Sciences Ltd. conducted an E...
Sources:
Tiziana Life Sciences Ltd’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Tiziana Life Sciences Ltd’s corporate clients.
For your research, we’ve provided 9 tables on Tiziana Life Sciences Ltd corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
